A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension.
2022-06-28
عنوان الدراسة
A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension.
داعم الدراسة
Actelion Pharmaceuticals Ltd
دواء الدراسة
Macitentan (ACT-064992, Opsumit ®)
رقم بروتوكول الدراسة
67896062CTP3001
حالة الدراسة
Completed
موقع الدراسة
King Fahad Medical City (Riyadh)
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.